Nwam LLC Grows Stock Holdings in Insmed, Inc. $INSM

Nwam LLC increased its position in Insmed, Inc. (NASDAQ:INSM) by 15.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 44,883 shares of the biopharmaceutical company’s stock after buying an additional 5,901 shares during the period. Nwam LLC’s holdings in Insmed were worth $7,339,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. CIBC Private Wealth Group LLC lifted its position in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares in the last quarter. CoreCap Advisors LLC purchased a new stake in shares of Insmed during the fourth quarter worth about $27,000. GraniteShares Advisors LLC bought a new stake in Insmed during the 4th quarter valued at approximately $30,000. Reflection Asset Management bought a new stake in Insmed during the 4th quarter valued at approximately $30,000. Finally, Raiffeisen Bank International AG bought a new stake in Insmed during the 4th quarter valued at approximately $32,000.

Insmed Price Performance

Insmed stock opened at $110.11 on Wednesday. The company has a market cap of $23.87 billion, a price-to-earnings ratio of -19.15 and a beta of 0.78. The firm’s fifty day moving average is $106.08 and its 200 day moving average is $137.07. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. Insmed, Inc. has a 52-week low of $90.39 and a 52-week high of $212.75.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The business had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. During the same period last year, the company posted ($1.42) EPS. The business’s revenue was up 229.7% on a year-over-year basis. Sell-side analysts forecast that Insmed, Inc. will post -2.55 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Morgan Stanley upgraded Insmed from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $166.00 to $212.00 in a research note on Monday, March 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research report on Tuesday, April 21st. Guggenheim reissued a “buy” rating and issued a $207.00 target price on shares of Insmed in a report on Friday, July 10th. Leerink Partners upped their target price on shares of Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 24th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Insmed in a research note on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.

Insider Buying and Selling at Insmed

In related news, insider Michael Alexander Smith sold 6,149 shares of the stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $108.47, for a total value of $666,982.03. Following the completion of the transaction, the insider owned 41,613 shares of the company’s stock, valued at approximately $4,513,762.11. This trade represents a 12.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO William Lewis sold 21,398 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $103.32, for a total value of $2,210,841.36. Following the completion of the sale, the chief executive officer directly owned 258,917 shares of the company’s stock, valued at $26,751,304.44. The trade was a 7.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 65,289 shares of company stock worth $7,334,073 in the last 90 days. 2.10% of the stock is currently owned by insiders.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.